Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum

Vaccine

Volumn 31, Issue 52, 2013, Pages 6185-6193

  De Villiers, Sabina H L ^a,b,c   Cornish, Katherine E ^a,c   Troska, Andrew J ^c   Pravetoni, Marco ^a,c,d   Pentel, Paul R ^a,c,d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

^c MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Antibody; Immunogen; Multivalent; Nicotine; Tobacco; Vaccine

Indexed keywords

1' N (2 MERCAPTOETHYL)PENTANAMIDE NICOTINE; 3' AMINOMETHYL NICOTINE; 6 (CARBOXYMETHYLUREIDO)NICOTINE; ALUMINUM POTASSIUM SULFATE; FREUND ADJUVANT; HAPTEN; IMIDE; KEYHOLE LIMPET HEMOCYANIN; MALEMIDE; NICOTINE; NICOTINE VACCINE; RECOMBINANT PROTEIN; RECOMBINANT PSEUDOMONAS AERUGINOSA EXOPROTEIN A; TRIPLE VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; IMMUNE RESPONSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VACCINATION;

ANTIBODY; IMMUNOGEN; MULTIVALENT; NICOTINE; TOBACCO; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, SUBCUTANEOUS; MALE; MODELS, ANIMAL; NICOTINE; RATS; SMOKING; VACCINATION; VACCINES;

EID: 84888433718     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.051     Document Type: Article

References (45)

1. WHO The World Health Report: 2003 Shaping the Future 2003, World Health Organization, Geneva.
2. WHO WHO fact sheet no. 339, may 2012 2012, World Health Organization, Geneva.
3. US Department of Health and Human Services The health consequences of smoking: nicotine addiction, a report of the surgeon general (publication no. CDC 88-8406). 1988, Public Health Service, Centers for Disease Control, Center for Health Promotion and Education, Office on Smoking and Health, Rockville, MD.
4. Jorenby D.E., Leischow S.J., Nides M.A., Rennard S.I., Johnston J.A., Hughes A.R., et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. NEJM 1999, 340(9):685-691.
5. McCarthy D.E., Piasecki T.M., Lawrence D.L., Jorenby D.E., Shiffman S., Fiore M.C., et al. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. Nicotine Tob Res 2008, 10(4):717-729.
6. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008, 3:CD006103.
7. Fagerstrom K., Hughes J. Varenicline in the treatment of tobacco dependence. Neuropsychiatr Dis Treat 2008, 4(2):353-363.
8. Hieda Y., Keyler D.E., Vandevoort J.T., Kane J.K., Ross C.A., Raphael D.E., et al. Active immunization alters the plasma nicotine concentration in rats. J Pharmacol Exp Ther 1997, 283(3):1076-1081.
9. Hieda Y., Keyler D.E., VanDeVoort J.T., Niedbala R.S., Raphael D.E., Ross C.A., et al. Immunization of rats reduces nicotine distribution to brain. Psychopharmacology (Berlin) 1999, 143(2):150-157.
10. Keyler D.E., Hieda Y., st Peter J., Pentel P.R. Altered disposition of repeated nicotine doses in rats immunized against nicotine. Nicotine Tob Res 1999, 1(3):241-249.
11. Hieda Y., Keyler D.E., Ennifar S., Fattom A., Pentel P.R. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int J Immunopharmacol 2000, 22(10):809-819.
12. Pentel P.R., Malin D.H., Ennifar S., Hieda Y., Keyler D.E., Lake J.R., et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol Biochem Behav 2000, 65(1):191-198.
13. Cerny E.H., Lévy R., Mauel J., Mpandi M., Mutter M., Henzelin-Nkubana C., et al. Preclinical development of a vaccine 'against smoking'. Onkologie 2002, 25(5):406-411.
14. de Villiers S.H., Lindblom N., Kalayanov G., Gordon S., Johansson A.M., Svensson T.H. Active immunization against nicotine alters the distribution of nicotine but not the metabolism to cotinine in the rat. Naunyn-Schmiedeberg's Arch Pharmacol 2004, 370(4):299-304.
15. Pravetoni M., Keyler D.E., Raleigh M.D., Harris A.C., Lesage M.G., Mattson C.K., et al. Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. Biochem Pharmacol 2011, 81(9):1164-1170.
16. Pravetoni M., Keyler D.E., Pidaparthi R.R., Carroll F.I., Runyon S.P., Murtaugh M.P., et al. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol 2012, 83(4):543-550.
17. de Villiers S.H., Lindblom N., Kalayanov G., Gordon S., Malmerfelt A., Johansson A.M., et al. Active immunization against nicotine suppresses nicotine-induced dopamine release in the rat nucleus accumbens shell. Respiration 2002, 69(3):247-253.
18. LeSage M.G., Keyler D.E., Hieda Y., Collins G., Burroughs D., Le C., et al. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology 2006, 184(3-4):409-416.
19. Moreno A.Y., Azar M.R., Warren N.A., Dickerson T.J., Koob G.F., Janda K.D. A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol Pharma 2010, 7(2):431-441.
20. Lindblom N., de Villiers S.H., Kalayanov G., Gordon S., Johansson A.M., Svensson T.H. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 2002, 69(3):254-260.
21. Cornuz J., Zwahlen S., Jungi W.F., Osterwalder J., Klingler K., van Melle G., et al. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008, 3(6):e2547.
22. Hatsukami D.K., Jorenby D.E., Gonzales D., Rigotti N.A., Glover E.D., Oncken C.A., et al. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin Pharmacol Ther 2011, 89(3):392-399.
23. Tonstad S., Heggen E., Giljam H., Lagerbäck PÅ, Tønnesen P., Wikingsson L.D., et al. Niccine(R), a nicotine vaccine, for relapse prevention: a phase II, randomized, placebo-controlled, multicenter clinical trial. Nicotine Tob Res 2013, [Epub ahead of print].
24. Hartmann-Boyce J., Cahill K., Hatsukami D., Cornuz J. Nicotine vaccines for smoking cessation. Cochrane Database of Syst Rev 2012, 8:CD007072.
25. Fahim R.E.F., Kessler P.D., Kalnik M.W. Therapeutic vaccines against tobacco addiction. Expert Rev Vac 2013, 12(3):333-342.
26. Keyler D.E., Roiko S.A., Earley C.A., Murtaugh M.P., Pentel P.R. Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 2008, 8(11):1589-1594.
27. Muller R. Determination of affinity and specificity of anti-hapten antibodies by competitive radioimmunoassay. Methods Enzymol 1983, 92:589-601.
28. Jacob P., Yu L., Wilson M., Benowitz N.L. Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans. Biol Mass Spectrom 1991, 20(5):247-252.
29. Khor S.P., Mayersohn M. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations. Drug Metab Dispos Biol Fate Chem 1991, 19(2):478-485.
30. Khor S.P., Bozigian H., Mayersohn M. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. II. Distribution of phencyclidine in the rat. Drug Metab Dispos Biol Fate Chem 1991, 19(2):486-490.
31. Triplett J.W., Hayden T.L., McWhorter L.K., Gautam S.R., Kim E.E., Bourne D.W. Determination of gallium concentration in blood-free tissues using a radiolabeled blood marker. J Pharm Sci 1985, 74(9):1007-1009.
32. Carrera M.R., Ashley J.A., Parsons L.H., Wirsching P., Koob G.F., Janda K.D. Suppression of psychoactive effects of cocaine by active immunization. Nature 1995, 378(6558):727-730.
33. Carrera M.R., Ashley J.A., Wirsching P., Koob G.F., Janda K.D. A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Nat Acad Sci USA 2001, 98(4):1988-1992.
34. Kantak K.M., Collins S.L., Lipman E.G., Bond J., Giovanoni K., Fox B.S. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berlin) 2000, 148(3):251-262.
35. Hrafnkelsdottir K., Valgeirsson J., Gizurarson S. Induction of protective and specific antibodies against cocaine by intranasal immunisation using a glyceride adjuvant. Biol Pharm Bull 2005, 28(6):1038-1042.
36. Danger Y., Devys A., Gadjou C., Galons H., Blanchard D., Follea G. Development of monoclonal antibodies directed against cocaine and cocaethylene: potential new tools for immunotherapy. Hybrid Hybridomics 2004, 23(4):212-218.
37. Berkowitz B., Spector S. Evidence for active immunity to morphine in mice. Science 1972, 178(67):1290-1292.
38. Bonese K.F., Wainer B.H., Fitch F.W., Rothberg R.M., Schuster C.R. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 1974, 252(5485):708-710.
39. Anton B., Leff P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 2006, 24(16):3232-3240.
40. Stowe G.N., Vendruscolo L.F., Edwards S., Schlosburg J.E., Misra K.K., Schulteis G., et al. A vaccine strategy that induces protective immunity against heroin. J Med Chem 2011, 54(14):5195-5204.
41. Pravetoni M., Raleigh M.D., Le Naour M., Tucker A.M., Harmon T.M., Jones J.M., et al. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine 2012, 30(31):4617-4624.
42. de Villiers S. Thesis: active immunization against nicotine dependence 2010, Karolinska Institutet, Stockholm. http://www.hdl.handle.net/10616/39817.
43. Kishimoto K., Altreuter D., Johnston L., Keller P., Pittet L. SEL-068 a fully synthetic nanoparticle vaccine for smoking cessation and relapse prevention. SRNT's 18th Annual Meeting 2012.
44. McCluskie M.J., Pryde D.C., Gervais D.P., Stead D.R., Zhang N., Benoit M., et al. Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. Int Immunopharmacol 2013, 16(1):50-56.
45. Rosenberg J., De B., Hicks M., Janda K., Kaminsky S., Worgall S., et al. Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based anti-nicotine vaccine. Hum Gene Ther 2013, 24:595-603.